Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04587856 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 22, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Mar 2024 to Mar 2025v5
  2. Primary and study completion dates: Jan 2024 to Mar 2024v4
  3. Study sites: 2 to 7v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Jan 2021 to Feb 12, 2021
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.
Trial Details
NCT Number NCT04587856
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions
(from sponsor)		 Myelodysplastic Syndromes
Related terms Myelodysplastic Syndromes
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov